npj Precision Oncology· 2017Q1· Review
The therapeutic potential of resveratrol: a review of clinical trials
- 862citations
- Q1SCImago
- 2017year
Short summary
Resveratrol shows promise in clinical trials for neurological disorders, cardiovascular diseases, and diabetes, improving biomarkers and demonstrating good tolerability, but yields mixed or detrimental results in certain cancers and NAFLD.
AI-generated from the title and abstract; the full text is not read.
Key points
- Resveratrol beneficially influences biomarkers for neurological disorders, cardiovascular diseases, and diabetes in clinical trials.
- Resveratrol shows ambiguous or detrimental effects in certain cancers and NAFLD.
- Poor bioavailability is a significant challenge limiting resveratrol's efficacy in clinical trials.
- Resveratrol is generally well-tolerated in human studies.
AI-generated from the title and abstract; the full text is not read.
Abstract
Resveratrol is a nutraceutical with several therapeutic effects. It has been shown to mimic effects of caloric restriction, exert anti-inflammatory and anti-oxidative effects, and affect the initiation and progression of many diseases through several mechanisms. While there is a wealth of in vitro and in vivo evidence that resveratrol could be a promising therapeutic agent, clinical trials must confirm its potential. In this work, we reviewed the current clinical data available regarding the pharmacological action of resveratrol. Most of the clinical trials of resveratrol have focused on cancer, neurological disorders, cardiovascular diseases, diabetes, non-alcoholic fatty liver disease (NAFLD), and obesity. We found that for neurological disorders, cardiovascular diseases, and diabetes, the current clinical trials show that resveratrol was well tolerated and beneficially influenced disease biomarkers. However resveratrol had ambiguous and sometimes even detrimental effects in certain types of cancers and in NAFLD. In most of the clinical trials, the major obstacle presented was resveratrol's poor bioavailability. Thus, this work provides useful considerations for the planning and design of future pre-clinical and clinical research on resveratrol.
The authors' abstract, as published at the source. npj Precision Oncology, 2017 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Geriatrics and Gerontology
Geriatrics and GerontologyMedicine